Angelini Ventures Signs €150 Million EIB Deal to Accelerate Biotech Innovation in Europe

The European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed a €150 million agreement to support the growth of European startups operating in biotechnology, medtech, and digital health. This agreement represents a strategic step for the sector: it is the first collaboration between the EIB and a European corporate venture capital arm in the healthcare space , a sign of the growing attention of EU institutions towards healthcare innovation.

The agreement provides for a joint commitment of €75 million each over the next six years, with the goal of making targeted co-investments in 7-10 startups deemed to have high potential and already approaching the commercial scalability stage. These startups are therefore not just early innovations, but projects capable of being transformed into clinical and technological solutions that can be effectively adopted by healthcare systems and industry.

A piece of the TechEU strategy

The initiative, presented at the Rome headquarters of Angelini Ventures, is part of TechEU , the EIB Group program that aims to strengthen Europe’s technological autonomy in strategic sectors—including life sciences, artificial intelligence, and deep tech.

The investment with Angelini Ventures is in the health and life sciences segment , a field in which Europe demonstrates cutting-edge scientific expertise but often struggles with technology transfer and attracting private capital.

Why it’s a significant agreement:

With this co-financing, the EIB and Angelini Ventures aim to bridge the investment gap compared to the United States and Asia in biotech and digital health startups; facilitate the transition from the laboratory to the market, accelerating the path of innovative clinical solutions; strengthen Europe’s ability to create and retain competitive technology companies; and foster an ecosystem in which corporations, institutions, and startups collaborate in a structured manner.

Angelini Ventures—already active in international investments in biotechnology, advanced therapies, mental health, and digital health—is thus positioning itself as one of Europe’s leading healthcare innovation hubs, serving as a bridge between research, industry, and institutional capital.

This operation looks to the future of European healthcare

In a context of rapidly growing demand for medical technologies, digital platforms, data-driven solutions, and new therapies, the partnership between the EIB and Angelini Ventures aims to generate a multiplier effect: catalyze further private investment and create the conditions for Europe to be not only a producer of science, but also an industrial leader in the healthcare of the future.

About Angelini Ventures

Angelini Ventures is the venture capital arm of the Angelini Industries group—the major Italian conglomerate that has been active for centuries in the pharmaceutical, healthcare, consumer care, and other sectors.

The fund was officially launched in 2022, with an initial commitment of €300 million to finance startups and emerging companies in the healthcare sector.

The underlying objective: to support “creators and companies that will shape the future of care” (in English on the website: “Shaping the future of care”) through investments in biotech, digital health, medtech, and life sciences.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PharmaStar. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.